Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS) Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction

NCT02752282
View directory record Official record
Conditions
Vaginal Bleeding, Uterine Cramping
Interventions
Anticipatory Counseling, Cancer Screening Guidelines
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 10, 2026, 10:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement

NCT01598662
View directory record Official record
Conditions
Contraception
Interventions
Mirena (levonorgestrel-releasing intrauterine system)
Device
Lead sponsor
University of Louisville
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 10, 2026, 10:24 PM EDT
Terminated No phase listed Observational

Contraceptive/HIV Affecting Risk in Adolescents

NCT03301480
View directory record Official record
Conditions
Contraception, Hiv
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Mirena Extension Trial

NCT02985541
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 10, 2026, 10:24 PM EDT
Withdrawn Not applicable Interventional

Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period

NCT01088178
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
16 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Efficacy and Safety of LevoCept

NCT02882191
View directory record Official record
Conditions
Contraception
Interventions
LevoCept
Drug
Lead sponsor
Sebela Women's Health Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
16
States / cities
Berkeley, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 10, 2026, 10:24 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

NCT04457076
View directory record Official record
Conditions
Contraception, Women at Risk for Pregnancy
Interventions
LevoCept
Drug
Lead sponsor
Sebela Women's Health Inc.
Industry
Eligibility
Up to 45 Years · Female only
Enrollment
1,525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
27
States / cities
Berkeley, California • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing IUD

NCT02799641
View directory record Official record
Conditions
Contraception
Interventions
Diazepam, Lidocaine, Placebo pill, Placebo injection
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 10, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

NCT00788671
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Contraceptives on Cervico-Vaginal Mucosa

NCT04814927
View directory record Official record
Conditions
Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions
Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 10, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

NCT00995150
View directory record Official record
Conditions
Contraception
Interventions
LNG20, Mirena
Drug
Lead sponsor
Medicines360
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
1,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

NCT03317795
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 10, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

NCT07382583
View directory record Official record
Conditions
Levonorgestrel, Intrauterine Systems, Prevention, Endometrial Cancer
Interventions
Survey using a questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding

NCT01555931
View directory record Official record
Conditions
Postpartum Contraception
Interventions
Levonorgestrel-releasing intrauterine system
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

NCT01613131
View directory record Official record
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception

NCT01240811
View directory record Official record
Conditions
Genital Tract Mucosal Immunity, Genital Tract Microflora
Interventions
IUD placement, Levonorgestrel IUD, Copper T380A IUD
Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 10, 2026, 10:24 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 10, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

NCT03182140
View directory record Official record
Conditions
Contraception
Interventions
Kyleena
Drug
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 10, 2026, 10:24 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period

NCT01161095
View directory record Official record
Conditions
Contraception, Postpartum Period
Interventions
LNG-IUS
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224
View directory record Official record
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 10, 2026, 10:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

NCT00635362
View directory record Official record
Conditions
Healthy
Interventions
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 10, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

NCT00528112
View directory record Official record
Conditions
Contraception
Interventions
LCS12, LCS16
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
2,885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
57
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 10, 2026, 10:24 PM EDT